Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection

• Published in: Antiviral therapy 2006, Vol.11 (2), p.255-261
• Main Authors: Kansu, Aydan, Doğanci, Tümay, Akman, Sezin A, Artan, Reha, Kuyucu, Necdet, Kalayci, Ayhan Gazi, Dikici, Bünyamin, Dalgiç, Buket, Selimoğlu, Ayşe, Kasirga, Erhun, Ozkan, Tanju B, Kuloğlu, Zarife, Aydoğdu, Sema, Boşnak, Mehmet, Ertekin, Vildan, Tanir, Gönül, Haspolat, Kenan, Girgin, Nurten, Yağci, Raşit Vural
• Format: Article
• Language: English
• Subjects: Adolescent; Alanine Transaminase - blood; Antiviral Agents - therapeutic use; Child; Child, Preschool; DNA, Viral - blood; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B e Antigens - blood; Hepatitis B, Chronic - drug therapy; Humans; Interferon-alpha - therapeutic use; Lamivudine - therapeutic use; Male; Recombinant Proteins; Sex Hormone-Binding Globulin; Viral Load
• ISSN: 1359-6535

To evaluate the efficacy of two regimens of combined interferon-alpha2a (IFN-alpha2a) and lamivudine (3TC) therapy in childhood chronic hepatitis B. A total of 177 patients received IFN-alpha2a, 9 million units (MU)/m2 for 6 months. In group I (112 patients, 8.7 +/- 3.5 years), 3TC (4 mg/kg/day, max 100 mg) was started simultaneously with IFN-alpha2a, in group II (65 patients, 9.6 +/- 3.8 years) 3TC was started 2 months prior to IFN-alpha2a. 3TC was continued for 6 months after antiHBe seroconversion or stopped at 24 months in nonresponders. Baseline alanine aminotransferase (ALT) was 134.2 +/- 34.1 and 147.0 +/- 45.3; histological activity index (HAI) was 7.4 +/- 2.7 and 7.1 +/- 2.3; and HBV DNA levels were above 2,000 pg/ml in 76% and 66% of patients in groups I and II, respectively (P > 0.005). Complete response was 55.3% and 27.6% in groups I and II, respectively (P < 0.01). AntiHBe seroconversion was higher and earlier, and HBV DNA clearance was earlier in group I (P < 0.05). HBsAg clearance was 12.5% and 4.6% and antiHBs seroconversion was 9.8% and 6.2% in groups I and II, respectively (P > 0.05). Breakthrough occurred in 17.9% and 24.6%; breakthrough times were 15.9 +/- 4.6 and 14.1 +/- 5.1 months; and relapse rates were 6.8% and none in groups I and II, respectively (P > 0.05, P > 0.05, P > 0.05). Responders had higher HAI (HAI > 6) and higher pre-treatment ALT than non-responders. Simultaneous 3TC+IFN-alpha2a yields a higher response and earlier antiHBe seroconversion and viral clearance than consecutive combined therapy. Relapse rate is low. Predictors of response are high basal ALT and high HAI scores. 3TC can be administered for 24 months without any side effect and breakthrough rate is comparable with previous studies.